{
  "docId": "019de074-cfba-73af-96cf-2b33e6c699c9",
  "docSlug": "90ad9e76f71a7983fe14e2a7d36252ee",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 28,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a four-column layout to present key findings from a clinical trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-cfba-73af-96cf-2b33e6c699c9/16",
  "deckHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9",
  "deckJsonHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9.json",
  "deckAnchorHref": "/decks/019de074-cfba-73af-96cf-2b33e6c699c9#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.23,
        "x": 0.76,
        "y": 0.294
      },
      "kind": "list",
      "text": "AB-729 was generally safe and well-tolerated after completing dosing in 41 patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c950c78-ffbb-4e4a-af3f-ad71005d7f2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.23,
        "x": 0.024,
        "y": 0.294
      },
      "kind": "list",
      "text": "AB-729 provided robust and comparable HBsAg declines regardless of dose, dosing interval, HBeAg or DNA status",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fdd01fa-46d0-49e6-bf79-b461ceddf836",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.23,
        "x": 0.515,
        "y": 0.294
      },
      "kind": "list",
      "text": "AB-729 results in HBV-specific T-cell immune restoration and decrease of exhausted T-cells in some patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b6287f2-fce9-4fc4-8c70-61f60752debd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.23,
        "x": 0.27,
        "y": 0.294
      },
      "kind": "list",
      "text": "Discontinuation of both AB-729 and NA-therapy results in sustained reduction in HBsAg and HBV DNA in 7 of 9 patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab534221-0407-4707-892b-362432849721",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.15,
        "x": 0.52,
        "y": 0.715
      },
      "kind": "source-note",
      "text": "*Data presented at EASL 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ee3c8ef-d137-4698-abb0-79164b13c242",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.075,
        "y": 0.06
      },
      "kind": "title",
      "text": "AB-729-001 Clinical Trial Key Takeaways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4481177-89cc-480a-b118-158326062372",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "5c74ebed-4ed2-4e0c-9827-b5b7aca9f01e",
      "evidence": "list/bullet: Discontinuation of both AB-729 and NA-therapy results in sustained reduction in HBsAg and HBV DNA in 7 of 9 patients",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 3,
      "beatId": "708d5cbd-cd14-4361-ab43-54fc6ba4b110",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Our Strategy, Broad Pipeline, AB-729 RNAi Therapeutic, and other solution-focused slides",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 16,
      "from": 10,
      "beatId": "506215b6-f901-48ef-83fa-7b3694884e17",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "AB-729-001 Phase 1a/1b Clinical Trial, Robust HBsAg declines, and AB-729-001 Clinical Trial Key Takeaways",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "94df7ae2-9303-427c-ba30-b5689743bab5",
      "evidence": "The document highlights the significant unmet medical need and the limitations of current treatment options.",
      "position": 1,
      "objective": "What are the consequences of not addressing HBV treatment?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}